Immunic, Inc. Reports Key Financial and Strategic Updates for Q1 2026

Immunic, Inc., a biotechnology company developing novel therapies for neurologic diseases, has released its financial results for the first quarter of 2026. The company appointed Michael A. Panzara, an acclaimed neurology expert, as Chief Medical Officer and has raised $200 million through a private placement, with potential for an additional $200 million.

The funds are intended to support ongoing development, including the phase 3 ENSURE trials of Vidofludimus Calcium for treating relapsing multiple sclerosis (RMS). This trial's top-line data is anticipated by the end of 2026, with plans for a New Drug Application in the U.S. by mid-2027.

Additionally, Immunic plans a phase 3 trial for primary progressive multiple sclerosis later this year. Financially, Immunic reported a net loss of $32.6 million for Q1 2026 and held cash reserves of $186.6 million, projected to fund operations into late 2027.